Literature DB >> 18686025

Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes.

Jason Levi Esses1, Jonathan Rosman, Lien Thanh Do, Paul Schweitzer, Sam Hanon.   

Abstract

A 56-year-old-man presented with syncope and torsades de pointes secondary to methadone-induced QT prolongation. After transition from methadone to buprenorphine, a partial mu-opiate-receptor agonist and a kappa-opiate-receptor antagonist, the QT normalized and ventricular arrhythmias resolved. Buprenorphine should be used for opiate dependence and chronic pain in patients with methadone-induced QT prolongation and as first line therapy in patients with risk factors for torsades de pointes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18686025     DOI： 10.1007/s10840-008-9280-8

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN： 1383-875X            Impact factor:   1.900


  7 in total

1.  Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

Authors:  Jennifer R Baker; Al M Best; Patricia A Pade; Elinore F McCance-Katz
Journal:  Ann Pharmacother       Date:  2006-02-28       Impact factor: 3.154

2.  Impact of methadone treatment on cardiac repolarization and conduction in opioid users.

Authors:  Bridget A Martell; Julia H Arnsten; Mori J Krantz; Marc N Gourevitch
Journal:  Am J Cardiol       Date:  2005-04-01       Impact factor: 2.778

3.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.

Authors:  Erich F Wedam; George E Bigelow; Rolley E Johnson; Paul A Nuzzo; Mark C P Haigney
Journal:  Arch Intern Med       Date:  2007-12-10

4.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

5.  A community-based evaluation of sudden death associated with therapeutic levels of methadone.

Authors:  Sumeet S Chugh; Carmen Socoteanu; Kyndaron Reinier; Justin Waltz; Jonathan Jui; Karen Gunson
Journal:  Am J Med       Date:  2008-01       Impact factor: 4.965

Review 6.  Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

Authors:  Akshay Gupta; Andrew T Lawrence; Kousik Krishnan; Clifford J Kavinsky; Richard G Trohman
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

7.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.

Authors:  Søren Fanoe; Christian Hvidt; Peter Ege; Gorm Boje Jensen
Journal:  Heart       Date:  2007-03-07       Impact factor: 5.994
  7 in total
  6 in total

1.  Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest.

Authors:  Geoffrey Walton; Seonaid Nolan; Christy Sutherland; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2015-09-21

2.  Ventricular arrhythmias in patients treated with methadone for opioid dependence.

Authors:  Sam Hanon; Randy M Seewald; Felix Yang; Paul Schweitzer; Jonathan Rosman
Journal:  J Interv Card Electrophysiol       Date:  2010-02-23       Impact factor: 1.900

Review 3.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

4.  Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.

Authors:  W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; Thomas Clausen; Jayanthi N Koneru; Christopher Kogut; Ericka L Breden Crouse; Jules C Hancox; Antony Fernandez; Ananda K Pandurangi
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

Review 5.  A systematic review of the cardiotoxicity of methadone.

Authors:  Samira Alinejad; Toba Kazemi; Nasim Zamani; Robert S Hoffman; Omid Mehrpour
Journal:  EXCLI J       Date:  2015-05-05       Impact factor: 4.068

6.  Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.

Authors:  Miaoying Shi; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2020-05-04       Impact factor: 5.153
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.